<DOC>
	<DOCNO>NCT00922610</DOCNO>
	<brief_summary>This study ass efficacy safety monthly administration Mircera Filipino patient chronic kidney disease either dialysis predialysis , receive erythropoiesis stimulate agents.Patients receive Mircera start dose 0.6 micrograms/kg sc every 2 week , dose adjustment target hemoglobin level achieve , dose continue every 4 week . The anticipated time study treatment 3-12 month , target sample &lt; 100 individual .</brief_summary>
	<brief_title>A Study Mircera Renal Anemia Among Filipino Chronic Kidney Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic kidney disease ; anemia ( Hb &gt; 8 &lt; 11 g/dL ) ; regular dialysis predialysis , treat ESA . transfusion red blood cell previous 8 week ; poorly control hypertension ; overt gastrointestinal bleeding , bleed necessitate transfusion previous 8 week ; active malignant disease ( except melanoma skin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>